-
1
-
-
0034917716
-
The human ATP-binding cassette (ABC) transporter superfamily
-
Dean M., Rzhetsky A., and Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 11 (2001) 1156-1166
-
(2001)
Genome Res.
, vol.11
, pp. 1156-1166
-
-
Dean, M.1
Rzhetsky, A.2
Allikmets, R.3
-
2
-
-
13044249156
-
A multidrug resistance transporter from human MCF-7 breast cancer cells
-
Doyle L.A., Yang W., Abruzzo L.V., Krogmann T., Gao Y., Rishi A.K., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 95 (1998) 15665-15670
-
(1998)
Proc. Natl. Acad. Sci. USA
, vol.95
, pp. 15665-15670
-
-
Doyle, L.A.1
Yang, W.2
Abruzzo, L.V.3
Krogmann, T.4
Gao, Y.5
Rishi, A.K.6
-
3
-
-
0032895533
-
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes
-
Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 59 (1999) 8-13
-
(1999)
Cancer Res.
, vol.59
, pp. 8-13
-
-
Miyake, K.1
Mickley, L.2
Litman, T.3
Zhan, Z.4
Robey, R.5
Cristensen, B.6
-
4
-
-
0032404092
-
A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance
-
Allikmets R., Schriml L.M., Hutchinson A., Romano-Spica V., and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res. 58 (1998) 5337-5339
-
(1998)
Cancer Res.
, vol.58
, pp. 5337-5339
-
-
Allikmets, R.1
Schriml, L.M.2
Hutchinson, A.3
Romano-Spica, V.4
Dean, M.5
-
5
-
-
0034947674
-
From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance
-
Litman T., Druley T.E., Stein W.D., and Bates S.E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. 58 (2001) 931-959
-
(2001)
Cell. Mol. Life Sci.
, vol.58
, pp. 931-959
-
-
Litman, T.1
Druley, T.E.2
Stein, W.D.3
Bates, S.E.4
-
6
-
-
0037050736
-
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization
-
Kage K., Tsukahara S., Sugiyama T., Asada S., Ishikawa E., Tsuruo T., et al. Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization. Int. J. Cancer 97 (2002) 626-630
-
(2002)
Int. J. Cancer
, vol.97
, pp. 626-630
-
-
Kage, K.1
Tsukahara, S.2
Sugiyama, T.3
Asada, S.4
Ishikawa, E.5
Tsuruo, T.6
-
7
-
-
0036732010
-
Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance
-
Volk E.L., Farley K.M., Wu Y., Li F., Robey R.W., and Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res. 62 (2002) 5035-5040
-
(2002)
Cancer Res.
, vol.62
, pp. 5035-5040
-
-
Volk, E.L.1
Farley, K.M.2
Wu, Y.3
Li, F.4
Robey, R.W.5
Schneider, E.6
-
8
-
-
0035834595
-
Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells
-
Nakatomi K., Yoshikawa M., Oka M., Ikegami Y., Hayasaka S., Sano K., et al. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun. 288 (2001) 827-832
-
(2001)
Biochem. Biophys. Res. Commun.
, vol.288
, pp. 827-832
-
-
Nakatomi, K.1
Yoshikawa, M.2
Oka, M.3
Ikegami, Y.4
Hayasaka, S.5
Sano, K.6
-
9
-
-
0034684120
-
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan
-
Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 92 (2000) 1651-1656
-
(2000)
J. Natl. Cancer Inst.
, vol.92
, pp. 1651-1656
-
-
Jonker, J.W.1
Smit, J.W.2
Brinkhuis, R.F.3
Maliepaard, M.4
Beijnen, J.H.5
Schellens, J.H.6
-
10
-
-
34547114499
-
Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution
-
Takenaka K., Morgan J.A., Scheffer G.L., Adachi M., Stewart C.F., Sun D., et al. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Res. 67 (2007) 6965-6972
-
(2007)
Cancer Res.
, vol.67
, pp. 6965-6972
-
-
Takenaka, K.1
Morgan, J.A.2
Scheffer, G.L.3
Adachi, M.4
Stewart, C.F.5
Sun, D.6
-
11
-
-
0035138482
-
Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells
-
Robey R.W., Medina-Perez W.Y., Nishiyama K., Lahusen T., Miyake K., Litman T., et al. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res. 7 (2001) 145-152
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 145-152
-
-
Robey, R.W.1
Medina-Perez, W.Y.2
Nishiyama, K.3
Lahusen, T.4
Miyake, K.5
Litman, T.6
-
12
-
-
0042068263
-
A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport
-
Mitomo H., Kato R., Ito A., Kasamatsu S., Ikegami Y., Kii I., et al. A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482 in methotrexate transport. Biochem. J. 373 (2003) 767-774
-
(2003)
Biochem. J.
, vol.373
, pp. 767-774
-
-
Mitomo, H.1
Kato, R.2
Ito, A.3
Kasamatsu, S.4
Ikegami, Y.5
Kii, I.6
-
13
-
-
0037130294
-
Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1
-
Hegedus T., Orfi L., Seprodi A., Varadi A., Sarkadi B., and Keri G. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. Biochim. Biophys. Acta 1587 (2002) 318-325
-
(2002)
Biochim. Biophys. Acta
, vol.1587
, pp. 318-325
-
-
Hegedus, T.1
Orfi, L.2
Seprodi, A.3
Varadi, A.4
Sarkadi, B.5
Keri, G.6
-
14
-
-
67349201915
-
-
S. Shukla, R.W. Robey, S.E. Bates, S.V. Ambudkar, Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2, Drug Metab. Dispos. (2008) [Epub ahead of print].
-
S. Shukla, R.W. Robey, S.E. Bates, S.V. Ambudkar, Sunitinib (Sutent(R), SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ABC transporters, P-glycoprotein (ABCB1) and ABCG2, Drug Metab. Dispos. (2008) [Epub ahead of print].
-
-
-
-
15
-
-
0035863314
-
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux
-
Erlichman C., Boerner S.A., Hallgren C.G., Spieker R., Wang X.Y., James C.D., et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 61 (2001) 739-748
-
(2001)
Cancer Res.
, vol.61
, pp. 739-748
-
-
Erlichman, C.1
Boerner, S.A.2
Hallgren, C.G.3
Spieker, R.4
Wang, X.Y.5
James, C.D.6
-
16
-
-
1942506722
-
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro
-
Houghton P.J., Germain G.S., Harwood F.C., Schuetz J.D., Stewart C.F., Buchdunger E., et al. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer Res. 64 (2004) 2333-2337
-
(2004)
Cancer Res.
, vol.64
, pp. 2333-2337
-
-
Houghton, P.J.1
Germain, G.S.2
Harwood, F.C.3
Schuetz, J.D.4
Stewart, C.F.5
Buchdunger, E.6
-
17
-
-
23744502215
-
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells
-
Kitazaki T., Oka M., Nakamura Y., Tsurutani J., Doi S., Yasunaga M., et al. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49 (2005) 337-343
-
(2005)
Lung Cancer
, vol.49
, pp. 337-343
-
-
Kitazaki, T.1
Oka, M.2
Nakamura, Y.3
Tsurutani, J.4
Doi, S.5
Yasunaga, M.6
-
18
-
-
13944269488
-
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance
-
Nakamura Y., Oka M., Soda H., Shiozawa K., Yoshikawa M., Itoh A., et al. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res. 65 (2005) 1541-1546
-
(2005)
Cancer Res.
, vol.65
, pp. 1541-1546
-
-
Nakamura, Y.1
Oka, M.2
Soda, H.3
Shiozawa, K.4
Yoshikawa, M.5
Itoh, A.6
-
19
-
-
33646404611
-
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo
-
Leggas M., Panetta J.C., Zhuang Y., Schuetz J.D., Johnston B., Bai F., et al. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Res. 66 (2006) 4802-4807
-
(2006)
Cancer Res.
, vol.66
, pp. 4802-4807
-
-
Leggas, M.1
Panetta, J.C.2
Zhuang, Y.3
Schuetz, J.D.4
Johnston, B.5
Bai, F.6
-
20
-
-
36348967305
-
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance
-
Shi Z., Peng X.X., Kim I.W., Shukla S., Si Q.S., Robey R.W., et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res. 67 (2007) 11012-11020
-
(2007)
Cancer Res.
, vol.67
, pp. 11012-11020
-
-
Shi, Z.1
Peng, X.X.2
Kim, I.W.3
Shukla, S.4
Si, Q.S.5
Robey, R.W.6
-
21
-
-
54249157033
-
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
-
Dai C.L., Tiwari A.K., Wu C.P., Su X.D., Wang S.R., Liu D.G., et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res. 68 (2008) 7905-7914
-
(2008)
Cancer Res.
, vol.68
, pp. 7905-7914
-
-
Dai, C.L.1
Tiwari, A.K.2
Wu, C.P.3
Su, X.D.4
Wang, S.R.5
Liu, D.G.6
-
22
-
-
78650874372
-
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
-
Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., and Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2 (2003) 471-478
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 471-478
-
-
Abrams, T.J.1
Lee, L.B.2
Murray, L.J.3
Pryer, N.K.4
Cherrington, J.M.5
-
23
-
-
0038204144
-
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
-
O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
-
(2003)
Blood
, vol.101
, pp. 3597-3605
-
-
O'Farrell, A.M.1
Abrams, T.J.2
Yuen, H.A.3
Ngai, T.J.4
Louie, S.G.5
Yee, K.W.6
-
24
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel D.B., Laird A.D., Xin X., Louie S.G., Christensen J.G., Li G., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9 (2003) 327-337
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
-
25
-
-
0347382812
-
Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity
-
Robey R.W., Honjo Y., Morisaki K., Nadjem T.A., Runge S., Risbood M., et al. Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity. Br. J. Cancer 89 (2003) 1971-1978
-
(2003)
Br. J. Cancer
, vol.89
, pp. 1971-1978
-
-
Robey, R.W.1
Honjo, Y.2
Morisaki, K.3
Nadjem, T.A.4
Runge, S.5
Risbood, M.6
-
26
-
-
32544451627
-
Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo
-
Shi Z., Liang Y.J., Chen Z.S., Wang X.W., Wang X.H., Fu L.W., et al. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol. Ther. 5 (2006) 39-47
-
(2006)
Cancer Biol. Ther.
, vol.5
, pp. 39-47
-
-
Shi, Z.1
Liang, Y.J.2
Chen, Z.S.3
Wang, X.W.4
Wang, X.H.5
Fu, L.W.6
-
27
-
-
0042354831
-
Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport
-
Chen Z.S., Robey R.W., Belinsky M.G., Shchaveleva I., Ren X.Q., Sugimoto Y., et al. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63 (2003) 4048-4054
-
(2003)
Cancer Res.
, vol.63
, pp. 4048-4054
-
-
Chen, Z.S.1
Robey, R.W.2
Belinsky, M.G.3
Shchaveleva, I.4
Ren, X.Q.5
Sugimoto, Y.6
-
28
-
-
38649135366
-
Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol
-
Gagnon V., Van Themsche C., Turner S., Leblanc V., and Asselin E. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol. Apoptosis 13 (2008) 259-271
-
(2008)
Apoptosis
, vol.13
, pp. 259-271
-
-
Gagnon, V.1
Van Themsche, C.2
Turner, S.3
Leblanc, V.4
Asselin, E.5
-
29
-
-
33646162869
-
ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance
-
Oh S.Y., Song J.H., Gil J.E., Kim J.H., Yeom Y.I., and Moon E.Y. ERK activation by thymosin-beta-4 (TB4) overexpression induces paclitaxel-resistance. Exp. Cell Res. 312 (2006) 1651-1657
-
(2006)
Exp. Cell Res.
, vol.312
, pp. 1651-1657
-
-
Oh, S.Y.1
Song, J.H.2
Gil, J.E.3
Kim, J.H.4
Yeom, Y.I.5
Moon, E.Y.6
-
30
-
-
34948887693
-
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
-
Mi Y., and Lou L. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br. J. Cancer 97 (2007) 934-940
-
(2007)
Br. J. Cancer
, vol.97
, pp. 934-940
-
-
Mi, Y.1
Lou, L.2
-
31
-
-
33744954585
-
Sunitinib in patients with metastatic renal cell carcinoma
-
Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
-
(2006)
JAMA
, vol.295
, pp. 2516-2524
-
-
Motzer, R.J.1
Rini, B.I.2
Bukowski, R.M.3
Curti, B.D.4
George, D.J.5
Hudes, G.R.6
-
32
-
-
33749665992
-
Sunitinib for imatinib-resistant GIST
-
Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 368 (2006) 1303-1304
-
(2006)
Lancet
, vol.368
, pp. 1303-1304
-
-
Joensuu, H.1
-
33
-
-
36048992408
-
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy
-
Saltz L.B., Rosen L.S., Marshall J.L., Belt R.J., Hurwitz H.I., Eckhardt S.G., et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol. 25 (2007) 4793-4799
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 4793-4799
-
-
Saltz, L.B.1
Rosen, L.S.2
Marshall, J.L.3
Belt, R.J.4
Hurwitz, H.I.5
Eckhardt, S.G.6
-
34
-
-
2442669093
-
Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer
-
Abrams T.J., Murray L.J., Pesenti E., Holway V.W., Colombo T., Lee L.B., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2 (2003) 1011-1021
-
(2003)
Mol. Cancer Ther.
, vol.2
, pp. 1011-1021
-
-
Abrams, T.J.1
Murray, L.J.2
Pesenti, E.3
Holway, V.W.4
Colombo, T.5
Lee, L.B.6
-
35
-
-
42949148257
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
Burstein H.J., Elias A.D., Rugo H.S., Cobleigh M.A., Wolff A.C., Eisenberg P.D., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26 (2008) 110-1816
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 110-1816
-
-
Burstein, H.J.1
Elias, A.D.2
Rugo, H.S.3
Cobleigh, M.A.4
Wolff, A.C.5
Eisenberg, P.D.6
-
36
-
-
39149120621
-
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer
-
Socinski M.A., Novello S., Brahmer J.R., Rosell R., Sanchez J.M., Belani C.P., et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J. Clin. Oncol. 26 (2008) 650-656
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 650-656
-
-
Socinski, M.A.1
Novello, S.2
Brahmer, J.R.3
Rosell, R.4
Sanchez, J.M.5
Belani, C.P.6
-
37
-
-
33947423448
-
Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
-
Goodman V.L., Rock E.P., Dagher R., Ramchandani R.P., Abraham S., Gobburu J.V., et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin. Cancer Res. 13 (2007) 1367-1373
-
(2007)
Clin. Cancer Res.
, vol.13
, pp. 1367-1373
-
-
Goodman, V.L.1
Rock, E.P.2
Dagher, R.3
Ramchandani, R.P.4
Abraham, S.5
Gobburu, J.V.6
-
38
-
-
10244277976
-
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells
-
Yee K.W., Schittenhelm M., O'Farrell A.M., Town A.R., McGreevey L., Bainbridge T., et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 104 (2004) 4202-4209
-
(2004)
Blood
, vol.104
, pp. 4202-4209
-
-
Yee, K.W.1
Schittenhelm, M.2
O'Farrell, A.M.3
Town, A.R.4
McGreevey, L.5
Bainbridge, T.6
-
39
-
-
14644446018
-
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
-
Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23 (2005) 939-952
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 939-952
-
-
Pietras, K.1
Hanahan, D.2
-
40
-
-
35848934106
-
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
-
Guerin O., Formento P., Lo Nigro C., Hofman P., Fischel J.L., Etienne-Grimaldi M.C., et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer. J. Cancer Res. Clin. Oncol. 134 (2008) 51-57
-
(2008)
J. Cancer Res. Clin. Oncol.
, vol.134
, pp. 51-57
-
-
Guerin, O.1
Formento, P.2
Lo Nigro, C.3
Hofman, P.4
Fischel, J.L.5
Etienne-Grimaldi, M.C.6
-
41
-
-
33847216496
-
Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies
-
Kessler T., Fehrmann F., Bieker R., Berdel W.E., and Mesters R.M. Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. Curr. Drug Targets 8 (2007) 257-268
-
(2007)
Curr. Drug Targets
, vol.8
, pp. 257-268
-
-
Kessler, T.1
Fehrmann, F.2
Bieker, R.3
Berdel, W.E.4
Mesters, R.M.5
-
42
-
-
27744551009
-
Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor
-
Roskoski Jr. R. Structure and regulation of Kit protein-tyrosine kinase - the stem cell factor receptor. Biochem. Biophys. Res. Commun. 338 (2005) 1307-1315
-
(2005)
Biochem. Biophys. Res. Commun.
, vol.338
, pp. 1307-1315
-
-
Roskoski Jr., R.1
-
43
-
-
0036968347
-
Activation of the PI3K/Akt pathway and chemotherapeutic resistance
-
West K.A., Castillo S.S., and Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist. Update. 5 (2002) 234-248
-
(2002)
Drug Resist. Update.
, vol.5
, pp. 234-248
-
-
West, K.A.1
Castillo, S.S.2
Dennis, P.A.3
-
44
-
-
0043163868
-
EGFR family signaling and its association with breast cancer development and resistance to chemotherapy
-
Navolanic P.M., Steelman L.S., and McCubrey J.A. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int. J. Oncol. 22 (2003) 237-252
-
(2003)
Int. J. Oncol.
, vol.22
, pp. 237-252
-
-
Navolanic, P.M.1
Steelman, L.S.2
McCubrey, J.A.3
-
45
-
-
0036091702
-
Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor
-
Taguchi T., Sonobe H., Toyonaga S., Yamasaki I., Shuin T., Takano A., et al. Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab. Invest. 82 (2002) 663-665
-
(2002)
Lab. Invest.
, vol.82
, pp. 663-665
-
-
Taguchi, T.1
Sonobe, H.2
Toyonaga, S.3
Yamasaki, I.4
Shuin, T.5
Takano, A.6
-
46
-
-
0035870289
-
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues
-
Maliepaard M., Scheffer G.L., Faneyte I.F., van Gastelen M.A., Pijnenborg A.C., Schinkel A.H., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61 (2001) 3458-3464
-
(2001)
Cancer Res.
, vol.61
, pp. 3458-3464
-
-
Maliepaard, M.1
Scheffer, G.L.2
Faneyte, I.F.3
van Gastelen, M.A.4
Pijnenborg, A.C.5
Schinkel, A.H.6
-
47
-
-
0036644903
-
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918
-
Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J. Clin. Oncol. 20 (2002) 2943-2950
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 2943-2950
-
-
Kruijtzer, C.M.1
Beijnen, J.H.2
Rosing, H.3
ten Bokkel Huinink, W.W.4
Schot, M.5
Jewell, R.C.6
|